Comparative trial of BBR 2778 (pixantrone) plus rituximab vs single agent rituximab in the treatment of relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).

被引：0
|
作者：
Santoro, A.
Voglova, J.
Gabrail, N.
Ciuleanu, T.
Liberati, M.
Hancock, B. W.
Stromatt, S.
Caballero, D.
机构：
[1] Ist Clin Humanitas, Rozzano, Italy
[2] Internal Clin, Dept Clin Haematol, Hradec Kralove, Czech Republic
[3] Gabrail Canc Ctr, Canton, OH USA
[4] Inst Oncol, Cluj Napoca, Romania
[5] Univ Perugia, I-06100 Perugia, Italy
[6] Weston Pk Hosp, Sheffield, S Yorkshire, England
[7] Cell Therapeut Inc, Seattle, WA USA
[8] Hosp Clin Salamanca, Serv Hematol, Salamanca, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2006年 / 24卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：441S / 441S
页数：1
相关论文
共 50 条
  • [1] Preliminary results of a phase I/II trial of BBR-2778 (Pixantrone) in combination with fludarabine, dexamethasone, and rituximab (FPD-R) in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Fayad, L
    Liebmann, J
    Modiano, M
    Cohen, GI
    Pro, B
    Romaguera, J
    Davite, C
    Lymboura, M
    Comis, S
    Laffranchi, BL
    BLOOD, 2004, 104 (11) : 373A - 373A
  • [2] Results of a phase I/II trial of pixantrone in combination with fludarabine, dexamethasone, and rituximab in the treatment of patients with relapsed/refractory indolent non-Hodgkin's lymphoma (NHL).
    Fayad, Luis
    Liebmann, James
    Modiano, Manuel
    Cohen, Gary
    Pro, Barbara
    Romaguera, Jorge
    Stromatt, Scott
    BLOOD, 2006, 108 (11) : 781A - 781A
  • [3] Pixantrone Dimaleate in Combination With Fludarabine, Dexamethasone, and Rituximab in Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma
    Srokowski, Tomasz P.
    Liebmann, James E.
    Modiano, Manuel R.
    Cohen, Gary I.
    Pro, Barbara
    Romaguera, Jorge E.
    Kuepfer, Christine
    Singer, Jack W.
    Fayad, Luis E.
    CANCER, 2011, 117 (22) : 5067 - 5073
  • [4] Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma
    Belada, David
    Georgiev, Pencho
    Dakhil, Shaker
    Inhorn, Lowell F.
    Andorsky, David
    Beck, J. Thaddeus
    Quick, Donald
    Pettengell, Ruth
    Daly, Robert
    Dean, James P.
    Pavlyuk, Mariya
    Failloux, Nelly
    Huebel, Kai
    FUTURE ONCOLOGY, 2016, 12 (15) : 1759 - 1768
  • [5] A phase I/II trial of BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).
    Camboni, G
    Fayad, L
    Tulpule, A
    Modiano, M
    Espina, BM
    Cabanillas, F
    Levine, AM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 580S - 580S
  • [6] Phase 3 trial of pixantrone plus rituximab versus gemcitabine plus rituximab in treating relapsed/refractory transplant-ineligible aggressive non-Hodgkin's lymphoma
    Georgiev, P. G.
    Belada, D.
    Dakhil, S.
    Inhorn, L. F.
    Andorsky, D.
    Liberati, A. M.
    Beck, J. T.
    Quick, D.
    Patti, C.
    Sivcheva, L.
    Zaucha, J. M.
    Pettengell, R.
    Devries, T.
    Dean, J. P.
    Pavlyuk, M.
    Failloux, N.
    Huebel, K.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL)
    Leonard, John
    Gribben, John G.
    Trneny, Marek
    Scheinberg, Phillip
    Kilavu, Nurgul
    Patturajan, Moore
    Fustier, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [8] Results of a phase I/II trial with BBR-2778 (pixantrone), methylprednisolone, cisplatin, and cytosine arabinoside (BSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).
    Levine, AM
    Fayad, L
    Tulpule, A
    Modiano, M
    Espina, BM
    Camboni, G
    Cabanillas, F
    BLOOD, 2003, 102 (11) : 640A - 640A
  • [9] Is first line single agent rituximab the best treatment for indolent non-Hodgkin's lymphoma? Update of a multicentric study comparing rituximab vs CNOP vs rituximab plus CNOP.
    Rivas-Vera, S
    Baez, E
    Sobrevilla-Calvo, P
    Baltazar, S
    Tripp, F
    Vela, J
    Garces, O
    Aguilar, L
    Ignacio, G
    Duque, J
    Rodriguez, P
    Reyes, G
    BLOOD, 2005, 106 (11) : 684A - 684A
  • [10] Introduction: Treatment of patients with rituximab-refractory indolent non-hodgkin's lymphoma
    Gregory, Stephanie A.
    SEMINARS IN HEMATOLOGY, 2007, 44 (03) : S1 - S1
12345